Background: Tumor immune microenvironment (TME) plays a key role in malignant pleural mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune checkpoint inhibitors as anticancer approach. This study retrospectively investigated TME and programmed death ligand 1 (PD-L1) expression in naïve MPM cases and their change under chemotherapy.
Introduction
Malignant pleural mesothelioma (MPM) is an occupational disease mainly due to asbestos exposure. Inhaled asbestos fibers cannot be broken down by the normal phagocytic process and persist in the pleural cavity, chronically activating macrophages, leading to the increase in the local immune infiltrate and malignant transformation of mesothelial cells [1, 2] .
Given the close interaction between the immune infiltrate and mesothelial cells, the prognostic role of the immune microenvironment was investigated, mainly on small and heterogeneous series without conclusive data [3] [4] [5] [6] .
High tumor-associated macrophages (TAMs) ratio with CD8þ and CD20þ cells were found to be independent predictors of worse overall survival (OS) [6] , while low lymphocyte to monocyte ratio in peripheral blood and tissue is reported to have negative prognostic significance [7] .
The programmed cell death pathway (PD-1/PD-L1) plays a critical role in tumor immune escape control. PD-1 is mainly expressed on activated CD4 T cells, CD8 T and B cells [8] . PD-L1, the ligand of PD-1, is not only expressed in immune cells but also in some cells including cancer cells helping immune evasion by interacting with PD-1 on T-cells [9, 10] .
On the basis of a high proportion of PD-L1 positive MPM, especially in nonepithelioid subgroup [11] [12] [13] , treatment with immune checkpoint inhibitors is under active investigation also in this disease. Despite the remarkable durability of responses seen in some patients, the overall response rates with immunotherapy remain 10%-20% [14] .
To date, PD-L1 expression has not shown a clear relationship with response to treatment in MPM [14, 15] . No evidence is available about the pathological features other than histology of MPM samples associated with different tumor immune microenvironment (TME) and checkpoint expression, and about their integrated prognostic value.
The primary aim of this retrospective study was to assess the TME and PD-L1 expression in epithelioid compared with nonepithelioid samples of a naïve MPM multicenter case series. Secondary end points were firstly to correlate TME and PD-L1 expression with several pathological features and patient outcome, then to develop a new composite prognostic score for patient stratification. TME and PD-L1 expression change after chemotherapy in a small subset of MPM samples was also explored.
Patients and methods

Patient samples and data collection
Starting from 2011, we centrally collected and analyzed epithelioid, biphasic, and sarcomatoid samples from the diagnostic biopsies of MPM patients who were referred to four Italian and one Slovenian cancer centers.
Chemo-naïve patients were considered eligible if they had a histological diagnosis of MPM, and adequate tumor samples for immunohistochemistry (IHC).
Clinical information about patients enrolled in the study was retrospectively collected.
Histology
Tissue samples were processed and classified according to the recent World Health Organization classification as epithelioid, biphasic, and sarcomatoid. For each chemo-naïve sample, necrosis and inflammation were evaluated over the entire tumor surface both in intratumoral and peritumoral areas and were quantified with a score of 0-3 (0: absent; 1: <10%; 2: 10%-20%; 3: >20%). Grading was categorized in three groups (I, II, and III) according to the nuclear grading system. Mitosis was counted in each square millimeter.
Immunohistochemistry
Inflammatory cell characterization was retrospectively carried out by IHC with specific antibodies. Immunoreactivity was expressed as percentage of positive cells on total inflammatory cells.
IHC for PD-L1 was also carried out. The positivity for PD-L1 was evaluated either in neoplastic cells or in the inflammatory background. Tumors with !1% of tumor cells were considered positive.
The proliferative index was expressed as number of Ki-67-positive cells on total cell number.
Statistics
The Mann-Whitney Rank Sum test was carried out to evaluate a different expression of TME and PD-L1 expression in the two histological subgroups and according to first-line treatment outcome. Correlation between TME and PD-L1 expression and tumor grading, necrosis, mitosis, and proliferation index were investigated through the Spearman linear correlation analysis.
OS curves were designed according to the Kaplan-Meier method. Univariate and multivariate analyses were carried out to show any possible impact of pathological parameters and clinical features on OS.
We further stratified patients according to a combined score based on the association of peritumoral and intratumoral CD8þ T lymphocytes, necrosis, mitosis, and proliferation index, which was considered in OS analysis. The differences between paired naïve and treated samples were assessed through Wilcoxon Signed Rank Test.
Further details on patients and methods are reported in the supplementary material, available at Annals of Oncology online.
Results
Patients
Ninety-three chemonaive MPM patients were enrolled in the study, 57 epithelioid and 36 nonepitheliod (22 biphasic and 14 sarcomatoid). Most patients were male, with ECOG PS 1, and a median age of 71 years. Patient characteristics are described in Table 1 . TME and PD-L1 expression in epithelioid compared with nonepithelioid MPM TME was evaluable in all 93 chemonaive MPM samples, while PD-L1 expression in 65 (36 epithelioid and 29 sarcomatoid/biphasic); 28 samples showed not sufficient tumor cells to be analyzed for PD-L1 expression.
Peritumoral infiltrates of CD4þ T lymphocytes (P ¼ 0.03) and CD20þ B lymphocytes (P ¼ 0.034) were statistically higher in epithelioid samples compared with nonepithelioid ( Figure 1A No significant difference in terms of PD-L1 expression on immune infiltrate was observed between the two histologic subgroups ( Figure 1F ).
Correlation of TME and PD-L1 expression with pathological features MPM samples with higher levels of CD68þ macrophages showed higher levels of CD8þ infiltrates at intratumoral [correlation coefficient (cc): 0.213; P ¼ 0.046] and peritumoral levels (cc: 0.234; P ¼ 0.033) (data not shown).
PD-L1 expression was significantly correlated with inflammatory cells, mainly in intratumoral areas (Table 2) .
When we analyzed TME and pathological features, we observed higher levels of CD8þ lymphocytes and CD68þ macrophages either in intratumoral or peritumoral areas and PD-L1 expression in tumors with higher levels of necrosis.
Higher PD-L1 expression on tumor cells was correlated with tumor grading in epithelioid samples (Table 2 and supplementary Figure S1A and S1B, available at Annals of Oncology online). Ki-67 was significantly correlated with peritumoral and intratumoral CD8þ lymphocytes (Table 2 and supplementary Figure  S1C and S1D, available at Annals of Oncology online).
Correlation of TME and PD-L1 expression with response to systemic treatment and patients outcome
Patients who achieved partial response/stable disease to first-line chemotherapy showed lower peritumoral CD3þ and CD8þ T lymphocytes, lower Ki-67, and mitosis. Even though not statistically significant, intratumoral CD3þ and CD8þ T lymphocytes were also lower in responders compared with progressive patients (supplementary Table S2 , available at Annals of Oncology online).
Univariate analysis for OS showed a negative prognostic value of high peritumoral and intratumoral CD8þ T-lymphocyte infiltrate, which was confirmed in the epithelioid subgroup ( Figure  2A and B and supplementary Figure S2 , available at Annals of Oncology online). Median OS was 14-16.5 months in MPM patients with lower peritumoral (P ¼ 0.007) and intratumoral (P < 0.001) CD8þ T lymphocytes, respectively, compared with 7.8 to 9.7 months in cases with higher CD8þ T lymphocytes, respectively.
In nonepithelioid subgroup, CD68þ/CD8þ ratio showed a negative prognostic impact, with shorter survival of cases with higher ratio (supplementary Figure S2 , available at Annals of Oncology online). Higher infiltrate of CD4þ T lymphocytes was associated with longer survival in the whole population (P ¼ 0.031) and in the epithelioid subgroup. Moreover, we confirmed a negative prognostic impact of other pathological features such as high necrosis, proliferation index, mitosis, and sarcomatoid/biphasic histologic subtype ( Figure 2D-G) .
When considering the 'combination score', patients with high levels of peritumoral and intratumoral CD8þ T lymphocytes, necrosis, mitosis, and proliferation index showed shorter OS ( Figure 2H ). Median OS in cases with a higher combination score was 11.3 months compared with 16.4 months in cases with a lower combination score (P < 0.003).
At multivariate analysis, the only significant features associated with OS were surgery and response to first-line chemotherapy (supplementary Table S3 , available at Annals of Oncology online).
Intratumor heterogeneity over time: TME and PD-L1 expression before and after chemotherapy Paired MPM specimens (14 epithelioid and 1 biphasic) obtained for diagnostic purposes before platinum-pemetrexed chemotherapy and at the time of resection were analyzed. After chemotherapy, MPM samples showed peritumoral and intratumoral increase in CD68þ macrophages and CD3þ T lymphocytes, even though only peritumoral CD3þ lymphocytes significantly increased (P ¼ 0.001) (supplementary Table S4 , available at Annals of Oncology online). Low levels of CD4þ and CD8þ lymphocytes were observed in naive samples, while after chemotherapy CD8þ significantly increased both at peritumoral (P ¼ 0.012) and intratumoral levels (P ¼ 0.05) ( Figures 3 and 4 and supplementary Table S4 , available at Annals of Oncology online). CD8þ/CD68þ ratio increased after chemotherapy, although without statistical significance (data not shown). Chemotherapy-induced PD-L1 expression in tumor cells (P ¼ 0.02) and even more in lymphomonocitic infiltrate (P ¼ 0.004) ( Figures 3 and 4 and supplementary Table S4 , available at Annals of Oncology online).
Discussion
Our work showed higher CD8þ T-lymphocyte infiltrate in MPM samples with aggressive biology (sarcomatoid/biphasic histology, higher necrosis, and proliferation index). Higher CD8þ Tlymphocyte infiltrate was associated with higher CD68þ macrophages and PD-L1 expression; moreover, PD-L1 expression was upregulated in sarcomatoid/biphasic and in epithelioid tumors with higher grading. While CD4þ T and CD20þ B lymphocytes infiltrate was associated with better prognosis, in line with the recent literature data on a wide epithelioid MPM case series [6] , CD8þ T lymphocytes and CD68þ macrophages infiltrate was associated with shorter survival, and CD68þ/CD8þ ratio evaluated in peritumoral stroma correlated with worse prognosis only in sarcomatoid/biphasic histotype. In contrast, most available literature data reported a favorable prognostic value of high levels of Tumor Infiltrating Lymphocytes in several tumors [16] [17] [18] and also in mesothelioma [3, 4] ; however, their true biological role in suppressing and promoting tumor growth and metastasis is governed by several positive or negative T-cell factors as the PD/ PD-L1 pathway. Tissue expression of PD-L1 has been reported in various tumors, including MPM, often associated with greater tumor aggressiveness and poor clinical outcome [11, 12, 19] . Indeed, PD-L1 expression could trigger a negative feedback loop favoring immune escape [13] . In our case series, high levels of CD8þ T lymphocytes concomitantly associated with high PD-L1 expression might explain our association with worse prognosis. Moreover, available series [3, 6, 7] included mostly epithelioid histotype, which might have its own prognostic value and often is suitable for surgery; on the contrary, our case series included balanced percentage of epithelioid and sarcomatoid/biphasic histologic subtypes, and this probably differentiates this work from other available.
Recent trials with checkpoint inhibitors in MPM showed that PD-L1 expression in tumor cells is not clearly predictive of a higher response rate [14, 15] . Thus, how can we optimize checkpoint inhibitor treatment outcome in MPM? Available evidence suggests that the answer lies in the tumor microenvironment, with particular reference to TAMs and their interconnection within the tumor and T cells [20] .
In our analysis, we also observed a considerable variation in the proportion of infiltrating cells and PD-L1 across tumor samples and this could explain why only a minority of PD-L1 positive mesotheliomas responded to pembrolizumab in the KEYNOTE-028 study [14] .
We used the cut-off point of 1% to define PD-L1 positive tumor samples; this was derived from clinical trials, even though other cut-off points would be of interest, the small number of cases assessed for PD-L1 expression limited this evaluation. All patients who underwent surgery showed lower CD8þ T-lymphocyte infiltrate and PD-L1 expression which increased after chemotherapy. The increase in PD-L1 expression was particularly evident in immune cells. These results could explain the failure of previous immunotherapy clinical trials, and suggest that combination strategies with immunotherapy, e.g. chemotherapy plus or before, could potentiate antitumor effects by promoting a robust T-cell response and favorable microenvironment for tumor antigen presentation and systemic immune response.
Today surgery is a controversial approach to MPM patients, thus the availability of specimens after cytotoxic treatments might be a challenge. However, on the basis of our results, it is tempting to speculate that a rebiopsy before inclusion in clinical trials with immunotherapeutic agents should be useful to estimate TME.
Conclusion
In summary, this is the first report that comprehensively evaluates tumor inflammatory cell distribution and PD-L1 protein expression in fragments from naïve mesothelioma-of all histologic subtypes-and in surgical specimens coming from a subset of the same patients who underwent surgery after systemic chemotherapy. The main limitations of the present work lie in the retrospective nature of our analyses, and in the lack of a validation set.
Recognition of the major actors playing a role in immune modulation, and their dynamicity over time and under chemotherapy pressure, might lead to new associations of immunogenic approaches for MPM treatment. Moreover, the identification of highly immunogenic tumor samples and their pathological features might help in patient selection for future clinical trials with anticancer immunotherapy and optimize the benefit and the cost-effectiveness of these drugs in MPM. A prospective confirmatory study might answer to these unmet needs. 
